NuVasive(R) Announces First Patients in Japan Treated With Precept(R) Posterior
SAN DIEGO, CA -- (Marketwired) -- 09/26/13 -- NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
announced today that the first surgeries were performed in Japan
using the Precept(R) posterior fixation system.
On July 31, 2013, NuVasive received regulatory Shonin approval for
Precept products, opening the door for the Company to offer a
minimally disruptive posterior fixation solution to patients and
surgeons in Japan. The approval furthers the Company's ability to
participate in the world's second largest spine market, where the
eXtreme Lateral Interbody Fusion (XLIF(R)) approach and other
posterior products were previously approved. The Precept Posterior
Fixation System provides surgeons with unprecedented ability to treat
a wide range of pathologies, all while offering an unparalleled ease
Surgeon proctors, who will instruct upcoming Precept training
courses, have started to schedule surgeries now that the new system
"We have our sights set on changing spine surgery and improving
patient outcomes in Japan, an exciting new market for us," said Alex
Lukianov, NuVasive Chairman and Chief Executive Officer. "With the
approval and launch of Precept, we can introduce Japanese surgeons to
additional innovation within our comprehensive portfolio of
procedurally integrated spine solutions."
Russell Powers, NuVasive Executive Vice President of International,
said, "We are absolutely thrilled to offer Precept in Japan, which
will advance our strategy of driving the shift toward minimally
disruptive approaches globally. Precept is a highly differentiated
solution with advanced guide technology, superior rod insertion
options, and multiple reduction capabilities. The initial reception
in Japan has been fantastic, and I applaud all of the NuVasive teams
who worked diligently to achieve this milestone."
The NuVasive Japan office officially opened in April 2013 in Tokyo,
Japan. The office is headed by NuVasive Executive Vice President of
Asia Pacific, Takaaki Tanaka. Tanaka-san has been with the Company
since 2009, and brings an extensive 20 years of experience in the
The Precept system offers the most advanced
technologies in guide design, rod insertion, set screw delivery, and
multiple reduction capabilities. Elegant yet powerful reduction
options, impressive compression/distraction systems, and efficient
instrumentation result in a system designed to address simple to the
most complex pathologies.
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally-integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 80
unique products developed to improve spine surgery and patient
outcomes. The Company's principal procedural solution is its Maximum
Access Surgery, or MAS(R), platform for lateral spine fusion. MAS was
designed to provide safe, reproducible, and clinically proven
outcomes, and is a highly differentiated solution with fully
integrated neuromonitoring, customizable exposure, and a broad
offering of application-specific implants and fixation devices
designed to address a variety of pathologies.
NuVasive's solutions are increasingly being adopted internationally,
as the Company lays the groundwork to continue growing as a global
business and to offer industry-leading, Absolutely Responsive
customer service to surgeons worldwide. NuVasive is focused on
becoming a $1 Billion Start-up(TM); taking market share by
maintaining a commitment to Superior Clinical Outcomes, Speed of
Innovation(R), and Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to those
risks and uncertainties more fully described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2414744
Press spacebar to pause and continue. Press esc to stop.